Clinical Trial Update: Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients [NA]

View source ↗

Summary

A completed clinical trial evaluating once-daily Envarsus to optimize immunosuppression management and outcomes in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunosuppression-related Conditions
• Kidney Transplant Recipients

Drugs mentioned

• Envarsus (tacrolimus)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Immunosuppression | NA | Status: COMPLETED | Results posted: 2019-12-24